https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-06 / Ther Apher Dial 2019 Jun;23(3):279-288
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-06 / Ther Apher Dial 2019 Jun;23(3):279-2882019-06-06 00:00:002019-06-06 00:00:00Phase I/II Pilot Study of Wilms‘ Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-03 / J Clin Oncol 37, 2019 (suppl; abstr 9538)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-03 / J Clin Oncol 37, 2019 (suppl; abstr 9538)2019-06-03 00:00:002020-08-26 12:15:23A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-02 / J Clin Oncol 37, 2019 (suppl; abstr 9039)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-02 / J Clin Oncol 37, 2019 (suppl; abstr 9039)2019-06-02 00:00:002020-05-06 15:07:38Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-01 / J Clin Oncol 37, 2019 (suppl; abstr 2639)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-01 / J Clin Oncol 37, 2019 (suppl; abstr 2639)2019-06-01 00:00:002019-06-01 00:00:00Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e20674)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e20674)2019-05-31 00:00:002019-05-31 00:00:00Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17005)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17005)2019-05-31 00:00:002019-05-31 00:00:00Dynamics of the immune status in patients with cervical cancer receiving complex treatment with dendritic cell vaccine.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e14212)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e14212)2019-05-31 00:00:002019-05-31 00:00:00Possible viral oncolysis by members of the Reoviridae and Paramyxoviridae families (an in vitro study).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17032)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17032)2019-05-31 00:00:002019-05-31 00:00:00A phase I trial evaluating the safety and efficacy of weekly paclitaxel or cisplatin with electro-hyperthermia in patients with recurrent or persistent epithelial ovarian, fallopian tubal or primary peritoneal carcinoma (KGOG 3030).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / Melanoma Manag 2019 May;6(2):MMT20
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / Melanoma Manag 2019 May;6(2):MMT202019-05-31 00:00:002019-05-31 00:00:00Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21024)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21024)2019-05-31 00:00:002020-05-06 15:04:34Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses.
